ETHORITY · INFOGRAPHIC · EN · Presentation format

AI-generated drugs reach Phase 3.

AI-supported breast screening cut screen-reading workload by 44%. The first late-stage trials, the evidence and the money in drug discovery, cancer care and ageing science.

27 Oct 2026

AI-generated drugs reach Phase 3. — Sources and qualifications remain in the original graphic. Select the image to read it at full size.

Download this figure · PNG Read the related publication

Read the text and sources

ETHORITY®AI Business Operating SystemTheme study

GOOD AI PRISM · THEME STUDY 2026/27 · PHARMA, BIOTECH & LONGEVITY

AI-generated drugs reach Phase 3.

AI-supported breast screening cut screen-reading workload by 44%. The first late-stage trials, the evidence and the money in drug discovery, cancer care and ageing science.

DiscoveryPhase 1Phase 2Phase 3

Phase 3

trials of generative-AI drugs have started

Source · Generate, Aug 2026; Insilico, Sep 2026

WITHOUT AIWITH AI−44%

−44%

screen-reading workload with AI-supported breast screening; cancers missed between screenings no worse (non-inferior)

Source · MASAI trial, The Lancet, 2026

$51.9bn2025$135.7bn

$135.7bn

out-licensing deals signed by Chinese drugmakers in 2025, up from $51.9bn

Source · PharmCube NextPharma, via Caixin, 14 Jan 2026

https://ethority.ai/research/publications/pharma-global-en · GLOBAL EDITION · EN · v1.7 · OCT 2026 · Good AI Prism artwork © 2026 ETHORITY & STEN.AI LLC · CC BY-NC-ND 4.0 · data and third-party marks not covered

The graphic is a separate publication format. Its edition does not replace the underlying study’s research window, dataset or PDF version.

Latest research, articles and tools